TCGA-OR-A5KV-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.367
- OXIDATIVE_PHOSPHORYLATION+0.356
- PANCREAS_BETA_CELLS+0.313
- MYC_TARGETS_V1+0.296
- KRAS_SIGNALING_DN+0.256
- CHOLESTEROL_HOMEOSTASIS+0.250
- SPERMATOGENESIS+0.249
- PEROXISOME+0.158
- GLYCOLYSIS+0.141
- DNA_REPAIR+0.132
Top 10 suppressed
- INTERFERON_GAMMA_RESPONSE-0.550
- INTERFERON_ALPHA_RESPONSE-0.543
- IL6_JAK_STAT3_SIGNALING-0.486
- INFLAMMATORY_RESPONSE-0.424
- ALLOGRAFT_REJECTION-0.375
- KRAS_SIGNALING_UP-0.352
- G2M_CHECKPOINT-0.328
- COMPLEMENT-0.325
- IL2_STAT5_SIGNALING-0.324
- E2F_TARGETS-0.324
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | cc1c7e4b-89a0-4d94-b9e5-293c2eacadd9 | — | — | 0.835 |
| 2 | R1 | — | — | 0.823 |
| 3 | 63e18642-fcf3-460b-95de-de16428dea6d | — | — | 0.817 |
| 4 | SRR12202489 | — | — | 0.809 |
| 5 | ERR2208968 | — | — | 0.806 |
| 6 | TCGA-CF-A47T-01A-11R-A23W-07 | — | — | 0.805 |
| 7 | SJEPD001539_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.798 |
| 8 | SRR25617838 | — | E | 0.797 |
| 9 | MNG42 | — | — | 0.795 |
| 10 | SRR2016956 | — | — | 0.793 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.367 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.356 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.313 | Cobimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.296 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.256 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.250 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.249 | Inavolisib | — uncovered |
| PEROXISOME | 0.158 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.141 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.132 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.124 | Inavolisib | — uncovered |
| HYPOXIA | 0.093 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.092 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.092 | Inavolisib | — uncovered |
| MYOGENESIS | 0.066 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.041 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.018 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.013 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.009 | Inavolisib | — uncovered |